Your Health, We Care
Another NameTAF、Tenofovir alafenamide Fumarate、替诺福韦艾拉酚胺、韦立得、替诺福韦二代
IndicationsIndicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older weighing at least 25 kg with compensated liver disease.
Specs
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
Tenofovir alafenamide fumarate tablets were initially approved in the United States in 2015, and the latest prescribing information revision was completed in March 2024.
Indicated for patients with chronic hepatitis B who are 6 years of age and older and weigh at least 25 kg.
The recommended dosage is one tablet once daily, to be taken with food. Reference article: Dosage and Administration of Tenofovir Alafenamide Fumarate Tablets
Dosage adjustment is required in patients with renal impairment; it is not recommended for patients with end-stage renal disease not receiving hemodialysis or for patients with decompensated liver disease.
Supportive treatment should be instituted in case of overdose; tenofovir can be effectively removed by hemodialysis.
Pharmacokinetically, the drug is rapidly absorbed after oral administration, is primarily eliminated via metabolism, and has a short half-life.
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
